These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887 [TBL] [Abstract][Full Text] [Related]
12. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects. Carmona MC; Louche K; Lefebvre B; Pilon A; Hennuyer N; Audinot-Bouchez V; Fievet C; Torpier G; Formstecher P; Renard P; Lefebvre P; Dacquet C; Staels B; Casteilla L; Pénicaud L; Diabetes; 2007 Nov; 56(11):2797-808. PubMed ID: 17704298 [TBL] [Abstract][Full Text] [Related]
13. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200 [TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Sommer M; Wolf G Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750 [TBL] [Abstract][Full Text] [Related]
16. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099 [TBL] [Abstract][Full Text] [Related]
17. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951 [TBL] [Abstract][Full Text] [Related]
18. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes. Kintscher U; Goebel M Curr Opin Investig Drugs; 2009 Apr; 10(4):381-7. PubMed ID: 19337960 [TBL] [Abstract][Full Text] [Related]
19. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]